Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

介入研究における予期せぬ対照群の行動

S Anttila, M Isokoski

    Lancet (London, England)
    |January 5, 1985
    PubMed
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    関連する概念動画

    こちらも読む

    関連記事

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    並び替え
    Same author

    Genetic alterations in p53 and k-ras in lung-cancer in relation to histopathology of the tumor and smoking history of the patient.

    International journal of oncology·2011
    Same author

    DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure.

    British journal of cancer·2009
    Same author

    Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH.

    Cytogenetic and genome research·2007
    Same author

    Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression.

    Journal of neural transmission (Vienna, Austria : 1996)·2007
    Same author

    Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer.

    Oncogene·2007
    Same author

    Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression.

    Journal of neural transmission (Vienna, Austria : 1996)·2006
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    関連記事をすべて見る